Literature DB >> 22375056

PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity.

Priyanka Tibarewal1, Georgios Zilidis, Laura Spinelli, Nick Schurch, Helene Maccario, Alexander Gray, Nevin M Perera, Lindsay Davidson, Geoffrey J Barton, Nick R Leslie.   

Abstract

The tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) has a well-characterized lipid phosphatase activity and a poorly characterized protein phosphatase activity. We show that both activities are required for PTEN to inhibit cellular invasion and to mediate most of its largest effects on gene expression. PTEN appears to dephosphorylate itself at threonine 366, and mutation of this site makes lipid phosphatase activity sufficient for PTEN to inhibit invasion. We propose that the dominant role for PTEN's protein phosphatase activity is autodephosphorylation-mediated regulation of its lipid phosphatase activity. Because PTEN's regulation of invasion and these changes in gene expression required lipid phosphatase activity, but did not correlate with the total cellular abundance of its phosphatidylinositol 3,4,5-trisphosphate (PIP₃) lipid substrate or AKT activity, we propose that localized PIP₃ signaling may play a role in those PTEN-mediated processes that depend on both its protein and lipid phosphatase activities. Finally, we identified a tumor-derived PTEN mutant selectively lacking protein phosphatase activity, indicating that in some circumstances the regulation of invasion and not that of AKT can correlate with PTEN-mediated tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22375056     DOI: 10.1126/scisignal.2002138

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  54 in total

1.  PTEN regulates PLK1 and controls chromosomal stability during cell division.

Authors:  Zhong Zhang; Sheng-Qi Hou; Jinxue He; Tingting Gu; Yuxin Yin; Wen H Shen
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

2.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 3.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

4.  Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function.

Authors:  Antonella Papa; Lixin Wan; Massimo Bonora; Leonardo Salmena; Min Sup Song; Robin M Hobbs; Andrea Lunardi; Kaitlyn Webster; Christopher Ng; Ryan H Newton; Nicholas Knoblauch; Jlenia Guarnerio; Keisuke Ito; Laurence A Turka; Andy H Beck; Paolo Pinton; Roderick T Bronson; Wenyi Wei; Pier Paolo Pandolfi
Journal:  Cell       Date:  2014-04-24       Impact factor: 41.582

5.  PTEN-GSK3β-MOB1 axis controls neurite outgrowth in vitro and in vivo.

Authors:  Zhiwen Song; Xiu Han; Hongjun Zou; Bin Zhang; Ya Ding; Xu Xu; Jian Zeng; Jinbo Liu; Aihua Gong
Journal:  Cell Mol Life Sci       Date:  2018-08-01       Impact factor: 9.261

6.  Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Authors:  Nilanjana Chatterjee; Evangelos Pazarentzos; Manasi K Mayekar; Philippe Gui; David V Allegakoen; Gorjan Hrustanovic; Victor Olivas; Luping Lin; Erik Verschueren; Jeffrey R Johnson; Matan Hofree; Jenny J Yan; Billy W Newton; John V Dollen; Charles H Earnshaw; Jennifer Flanagan; Elton Chan; Saurabh Asthana; Trey Ideker; Wei Wu; Junji Suzuki; Benjamin A Barad; Yuriy Kirichok; James S Fraser; William A Weiss; Nevan J Krogan; Asmin Tulpule; Amit J Sabnis; Trever G Bivona
Journal:  Cell Rep       Date:  2019-08-27       Impact factor: 9.423

7.  PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion.

Authors:  Sarah M Mense; Douglas Barrows; Cindy Hodakoski; Nicole Steinbach; David Schoenfeld; William Su; Benjamin D Hopkins; Tao Su; Barry Fine; Hanina Hibshoosh; Ramon Parsons
Journal:  Sci Signal       Date:  2015-03-31       Impact factor: 8.192

Review 8.  Neomorphic mutations create therapeutic challenges in cancer.

Authors:  V Takiar; C K M Ip; M Gao; G B Mills; L W T Cheung
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

9.  PTEN is a protein tyrosine phosphatase for IRS1.

Authors:  Yuji Shi; Junru Wang; Sarat Chandarlapaty; Justin Cross; Craig Thompson; Neal Rosen; Xuejun Jiang
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

Review 10.  Regulation and modulation of PTEN activity.

Authors:  Elahe Naderali; Amir Afshin Khaki; Jafar Soleymani Rad; Alireza Ali-Hemmati; Mohammad Rahmati; Hojjatollah Nozad Charoudeh
Journal:  Mol Biol Rep       Date:  2018-08-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.